Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma

Publication Date: March 1, 2021

Key Points

Key Points

  • Nasopharyngeal carcinoma (NPC) is uncommon in many jurisdictions but remains a significant public health problem in East and Southeast Asia, which accounted for more than 70% of the approximate 129,000 new diagnoses worldwide in 2018.
  • NPC relies almost exclusively on (chemo-)radiotherapy to achieve disease control in most presentations, particularly in the definitive treatment of stage II to IVA disease.

Treatment

...eatmen...

...: For Patients with Stage II to IVA N...

...endation 1.1For all nasopharyngeal carcinoma...

Recommendation 1.2For all NPC patients, both se...

...ation 1.3For all NPC patients, a prescribed dos...

....4For all NPC patients, gross tumor volume should...

...1.5For NPC patients who have undergone i...

...tion 1.6The delineation of elective...


...emotherapy Sequence

....1For T2N0 (AJCC 8th) NPC patients, chem...

...ation 2.2For T1-2N1 (AJCC 8th) NPC pati...

...mendation 2.3For Stage III–IVA (exc...

...commendation 2.4For Stage III–IVA (...

...n 2.5For T3N0 (AJCC 8th) NPC patients, con...


...rent Chemotherapy

...on 3.1For all NPC patients without contraindicati...

...mmendation 3.2For all NPC patients without c...

...ommendation 3.3For NPC patients wi...

...mendation 3.4For NPC patients with a contraindic...


Induction Chemo...

...commendation 4.1For all NPC patients...

...ion 4.2For NPC patients receiving induction...

....3For NPC patients receiving induct...


...ant Chemotherapy

...mmendation 5.1For all NPC patients receiving a...

...5.2For all NPC patients receiving adjuvant chemo...

...mmendation 5.3For all NPC patients receiving a...


.... Stage II to IVA Nasopharyngeal Carcinom...